SUNDAY  7TH  OCTOBER  2007

14:00 – 14.20  Welcome and Introduction

Giovanni Gaviraghi, Chairman
Silvano Focardi, Rector University of Siena
David Rotella, President, ACS
Roberto Pellicciari, President, EFMC
Luisa Mosti, President, Division of Medicinal Chemistry ICS

PLENARY LECTURES , Chair - Giovanni Gaviraghi


15:05 – 15:50  Carlo Melchiorre, University of Bologna (UNIBO): Multi-Target-Directed Drugs for Neurodegeneration

15:50 – 16:10  Coffee Break

HIT TO LEAD TO CANDIDATE

16:10 -16:50  David Rees, Astex Therapeutics: Fragment Based Drug Discovery: from Crystal to Clinic

16:50 -17:30  Daniele Donati, GSK Psychiatry CEDD Verona: Identification and Optimisation of a Novel Series of Selective 5HT2c Antagonists

17:30 -18:10  Jeffery Albert, AstraZeneca Pharmaceuticals Wilmington DE: Fragment-Based Lead Generation and Structure-Based Design for the Discovery of High Affinity β-Secretase Inhibitors

18:30 -19:50  POSTER SESSION 1

20:00  Welcome Reception – Santa Maria della Scala
MONDAY 8TH OCTOBER 2007

CANCER - Chair – Peter Wipf, Univ. of Pittsburgh

09:00 – 09:40  Antonello Mai, Università degli Studi Roma, (UNIRoma):
               Epigenetic Small Molecule Modulators and Cancer: An Overview

09:40 – 10:20  David Newman, NCI, Frederick, MD:
               Mother Nature’s Gifts to Cancer Chemotherapy

10:20 – 10:40  Coffee Break

10:40 – 11:20  William Gerwick, University of California, San Diego, San Diego CA:
               Cancer Drug Discovery from Marine Cyanobacteria using Mechanism-
               Based and Mechanism-Blind Approaches

11:20 – 12:00  Christopher Straub, Novartis:
               Inhibitors of Apoptosis Proteins: Application of Structure Based Drug
               Design to the Taming of a Protein-Protein Interaction Target

12:00 – 12:20  2 Short Talks selected from Poster Presentations

12:30 – 14:00  Lunch

CNS - Chair - Graeme Robertson, Siena Biotech SpA

14:00 – 14:40  Giuseppe Ronsisvalle, University of Catania (UNICT):
               Selective sigma Ligands and their Role in Neurodegeneration

14:40 – 15:20  Albert Robichaud, Wyeth Research Princeton NJ:
               Design and SAR of Potent, Selective 5-HT6 Ligands and their Potential
               Utility as CNS Disease Therapeutics

15:20 – 15:40  Coffee Break

15:40 – 16:20  Angelo Carotti, University of Bari (UNIBA):
               The MAO’s Long March: From Toxic First-generation Drugs to
               Isoform-selective, Reversible and Multitarget Inhibitors
16.20 – 17:00  
Arun Ghosh, Purdue University, West Lafayette, IN:  
Design of Potent and Selective Memapsin 2 (β-Secretase) Inhibitors  
for Alzheimer's Disease

17:00 – 17:20  
2 Short Talks selected from Poster Presentations

17:30 – 19:00  
POSTER SESSION 2

19:30  
Teatro dei Rozzi – Concert “Great Opera Arias”
TUESDAY 9TH OCTOBER 2007

CANCER - Chair – Roberto Pellicciari, Univ. of Perugia, EFMC President

09:00 – 09:40  Maurizio Botta, Università degli Studi di Siena, (UNISI): Small Molecule Kinases Inhibitors: from Virtual Screening to in Vitro and in Vivo Studies

09:40 – 10:20  Pier Giovanni Baraldi, University of Ferrara (UNIFE): DNA Minor Groove Binders (MGB) and Tubulin Inhibitors as Antitumor Agents

10:20 – 10:40  Coffee Break

10:40 – 11:20  Thomas Miller, Merck Research laboratories, Boston: Histone Deacetylase Inhibitors

11:20 – 12:00  Maurizio Pulici, Nerviano Medical Sciences: Aurora Kinase Inhibition: Identification and Expansion of Novel Scaffolds Leading to a Potent and Selective Compound with Favourable Antitumour Kinase Inhibition Profile

12:00 – 12:20  2 Short Talks selected from Poster Presentations

12:20 – 14:00  Lunch

CNS – Chair David Rotella, Wyeth Pharmaceuticals

14:00 – 14:40  Deen Tulshian, Schering Plough Research Institute, Kenilworth NJ: Discovery of Orally Active Nociceptin Receptor Agonists for the Management of Anxiety and Cough

14:40 – 15:20  Chiara Ghiron, Siena Biotech Spa: The Discovery of a Novel Series of Alpha7 nAChR Agonists

15:20 – 15:40  Coffee Break

15:40 – 16:20  Stefano Moro, University of Padova (UNIPD): Protein Misfolding and Neurodegeneration

16:20 – 17:00  James Monn, Eli Lilly, Indianapolis: Discovery of mGlu2/3 Receptor Agonists for the Treatment of Psychiatric Disorders

17:00 – 17:10  Roberto Pellicciari (EFMC), Dave Rotella (ACS Medi): Closure – Conference Summary and Future Perspectives

20:30  Conference Dinner “Enoteca Italiana”, Siena